2023
Cellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell types
2018
Increased levels of circulating MMP3 correlate with severe rejection in face transplantation
Kollar B, Shubin A, Borges T, Tasigiorgos S, Win T, Lian C, Dillon S, Gu X, Wyrobnik I, Murphy G, Pomahac B, Libermann T, Riella L. Increased levels of circulating MMP3 correlate with severe rejection in face transplantation. Scientific Reports 2018, 8: 14915. PMID: 30297859, PMCID: PMC6175842, DOI: 10.1038/s41598-018-33272-7.Peer-Reviewed Original ResearchConceptsSevere rejectionFace transplantationLarge independent patient cohortsAcute rejection episodesAnti-rejection treatmentFirst postoperative yearLongitudinal serum samplesNon-invasive candidate biomarkersViable treatment optionSOMAscan proteomics platformIndependent patient cohortsFace transplant recipientsRejection episodesPostoperative yearTransplant recipientsDevastating injuriesMMP3 levelsTransplant rejectionHistological gradePatient cohortTreatment optionsSurrogate markerMMP3 proteinCandidate biomarkersTransplantation